Sangamo Biosciences (SGMO) is a not yet profitable biotech developing gene regulating biotherapeutics for unmet medical needs. Its proprietary technology platform allows Sangamo to modify naturally occurring zinc finger DNA-binding proteins (ZFPs) into proteins that can modify, activate or deactivate specific DNA sequences.
Image Source: Sangamo SEC filings
Before going any further, it's important to understand that I am providing a very simplified explanation of Sangamo's technology and the science behind it. My intention is to provide investors with enough background to understand the company's potential advantage over competitors, not to administer a university level genetics course. If you want to know more, I suggest visiting the company's website and 10-K filings for...
Only subscribers can access this article, which is part of the PRO research library covering 3,773 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: